toledo sfc-multigram system (METTLER TOLEDO)
90
Structured Review
METTLER TOLEDO
toledo sfc-multigram system
Toledo Sfc Multigram System, supplied by METTLER TOLEDO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multigram/toledo+multigram+iii+system+sfc/pm40198752-206-23-23
Average 90 stars, based on 1 article reviews
Toledo Sfc Multigram System, supplied by METTLER TOLEDO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multigram/toledo+multigram+iii+system+sfc/pm40198752-206-23-23
Average 90 stars, based on 1 article reviews
toledo sfc-multigram system - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Solvent:Article Title: Benzothiazole compounds for the treatment of autoimmune diseases Article Snippet: Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Article Title: Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections Article Snippet: ; VWR International, Bridgeport, N.J.; Varian Inc., Palo Alto, Calif., and Article Title: Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. Article Snippet: Described herein is the first-time disclosure of Linvencorvir (RG7907), a clinical compound and a hepatitis B virus (HBV) core protein allosteric modulator, for the treatment of chronic HBV infection.. Built upon the core structure of hetero aryl dihydropyrimidine, RG7907 was rationally designed by combining all the drug-like features of low CYP3A4 induction, potent antiHBV activity, high metabolic stability, low hERG liability, and favorable animal pharmacokinetic (PK) profiles.. In particular, the chemistry strategy to mitigate CYP3A4 induction through introducing a large, rigid, and polar substituent at the position that has less interaction with the therapeutic biological target (HBV core proteins herein) is of general interest to the medicinal chemistry community. Article Title: Piperazine compounds for the treatment of autoimmune disease Article Snippet: Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge Prep-C18 (5 μm, OBDTM 30×100 mm) column, SunFire Prep-C18 (5 μm, OBD 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Article Title: Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy. Article Snippet: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy.. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency.. The hit featured a quinolinone central core and a phenol headgroup. Article Title: Dihydropyrrolopyridine inhibitors of ROR-gamma Article Snippet: The residue was purified by Article Title: Aminocarbamoyl compounds for the treatment of viral infections Article Snippet: LC/MS spectra were obtained using a Waters UPLC-SQD Mass. Indirect Immunoperoxidase Assay:Article Title: Benzothiazole compounds for the treatment of autoimmune diseases Article Snippet: Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Article Title: Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections Article Snippet: ; VWR International, Bridgeport, N.J.; Varian Inc., Palo Alto, Calif., and Article Title: Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. Article Snippet: Described herein is the first-time disclosure of Linvencorvir (RG7907), a clinical compound and a hepatitis B virus (HBV) core protein allosteric modulator, for the treatment of chronic HBV infection.. Built upon the core structure of hetero aryl dihydropyrimidine, RG7907 was rationally designed by combining all the drug-like features of low CYP3A4 induction, potent antiHBV activity, high metabolic stability, low hERG liability, and favorable animal pharmacokinetic (PK) profiles.. In particular, the chemistry strategy to mitigate CYP3A4 induction through introducing a large, rigid, and polar substituent at the position that has less interaction with the therapeutic biological target (HBV core proteins herein) is of general interest to the medicinal chemistry community. Article Title: Piperazine compounds for the treatment of autoimmune disease Article Snippet: Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge Prep-C18 (5 μm, OBDTM 30×100 mm) column, SunFire Prep-C18 (5 μm, OBD 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Article Title: Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy. Article Snippet: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy.. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency.. The hit featured a quinolinone central core and a phenol headgroup. Article Title: Dihydropyrrolopyridine inhibitors of ROR-gamma Article Snippet: The residue was purified by Article Title: Aminocarbamoyl compounds for the treatment of viral infections Article Snippet: LC/MS spectra were obtained using a Waters UPLC-SQD Mass. Residue:Article Title: Benzothiazole compounds for the treatment of autoimmune diseases Article Snippet: Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Article Title: Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections Article Snippet: ; VWR International, Bridgeport, N.J.; Varian Inc., Palo Alto, Calif., and Article Title: Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. Article Snippet: Described herein is the first-time disclosure of Linvencorvir (RG7907), a clinical compound and a hepatitis B virus (HBV) core protein allosteric modulator, for the treatment of chronic HBV infection.. Built upon the core structure of hetero aryl dihydropyrimidine, RG7907 was rationally designed by combining all the drug-like features of low CYP3A4 induction, potent antiHBV activity, high metabolic stability, low hERG liability, and favorable animal pharmacokinetic (PK) profiles.. In particular, the chemistry strategy to mitigate CYP3A4 induction through introducing a large, rigid, and polar substituent at the position that has less interaction with the therapeutic biological target (HBV core proteins herein) is of general interest to the medicinal chemistry community. Article Title: Piperazine compounds for the treatment of autoimmune disease Article Snippet: Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge Prep-C18 (5 μm, OBDTM 30×100 mm) column, SunFire Prep-C18 (5 μm, OBD 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Article Title: Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy. Article Snippet: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy.. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency.. The hit featured a quinolinone central core and a phenol headgroup. Article Title: Dihydropyrrolopyridine inhibitors of ROR-gamma Article Snippet: The residue was purified by Article Title: Aminocarbamoyl compounds for the treatment of viral infections Article Snippet: LC/MS spectra were obtained using a Waters UPLC-SQD Mass. Purification:Article Title: Benzothiazole compounds for the treatment of autoimmune diseases Article Snippet: Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Article Title: Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections Article Snippet: ; VWR International, Bridgeport, N.J.; Varian Inc., Palo Alto, Calif., and Article Title: Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. Article Snippet: Described herein is the first-time disclosure of Linvencorvir (RG7907), a clinical compound and a hepatitis B virus (HBV) core protein allosteric modulator, for the treatment of chronic HBV infection.. Built upon the core structure of hetero aryl dihydropyrimidine, RG7907 was rationally designed by combining all the drug-like features of low CYP3A4 induction, potent antiHBV activity, high metabolic stability, low hERG liability, and favorable animal pharmacokinetic (PK) profiles.. In particular, the chemistry strategy to mitigate CYP3A4 induction through introducing a large, rigid, and polar substituent at the position that has less interaction with the therapeutic biological target (HBV core proteins herein) is of general interest to the medicinal chemistry community. Article Title: Piperazine compounds for the treatment of autoimmune disease Article Snippet: Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge Prep-C18 (5 μm, OBDTM 30×100 mm) column, SunFire Prep-C18 (5 μm, OBD 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Article Title: Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy. Article Snippet: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy.. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency.. The hit featured a quinolinone central core and a phenol headgroup. Article Title: Dihydropyrrolopyridine inhibitors of ROR-gamma Article Snippet: The residue was purified by Article Title: Aminocarbamoyl compounds for the treatment of viral infections Article Snippet: LC/MS spectra were obtained using a Waters UPLC-SQD Mass. Chromatography:Article Title: Benzothiazole compounds for the treatment of autoimmune diseases Article Snippet: Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Article Title: Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections Article Snippet: ; VWR International, Bridgeport, N.J.; Varian Inc., Palo Alto, Calif., and Article Title: Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. Article Snippet: Described herein is the first-time disclosure of Linvencorvir (RG7907), a clinical compound and a hepatitis B virus (HBV) core protein allosteric modulator, for the treatment of chronic HBV infection.. Built upon the core structure of hetero aryl dihydropyrimidine, RG7907 was rationally designed by combining all the drug-like features of low CYP3A4 induction, potent antiHBV activity, high metabolic stability, low hERG liability, and favorable animal pharmacokinetic (PK) profiles.. In particular, the chemistry strategy to mitigate CYP3A4 induction through introducing a large, rigid, and polar substituent at the position that has less interaction with the therapeutic biological target (HBV core proteins herein) is of general interest to the medicinal chemistry community. Article Title: Piperazine compounds for the treatment of autoimmune disease Article Snippet: Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge Prep-C18 (5 μm, OBDTM 30×100 mm) column, SunFire Prep-C18 (5 μm, OBD 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Article Title: Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy. Article Snippet: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy.. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency.. The hit featured a quinolinone central core and a phenol headgroup. Article Title: Dihydropyrrolopyridine inhibitors of ROR-gamma Article Snippet: The residue was purified by Article Title: Aminocarbamoyl compounds for the treatment of viral infections Article Snippet: LC/MS spectra were obtained using a Waters UPLC-SQD Mass. |